These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11590629)

  • 1. A three-stage clinical trial design for rare disorders.
    Honkanen VE; Siegel AF; Szalai JP; Berger V; Feldman BM; Siegel JN
    Stat Med; 2001 Oct; 20(20):3009-21. PubMed ID: 11590629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An analysis of adaptive design variations on the sequential parallel comparison design for clinical trials.
    Mi MY; Betensky RA
    Clin Trials; 2013 Apr; 10(2):207-15. PubMed ID: 23283576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size in orthodontic randomized controlled trials: are numbers justified?
    Koletsi D; Pandis N; Fleming PS
    Eur J Orthod; 2014 Feb; 36(1):67-73. PubMed ID: 23460731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A two-way enriched clinical trial design: combining advantages of placebo lead-in and randomized withdrawal.
    Ivanova A; Tamura RN
    Stat Methods Med Res; 2015 Dec; 24(6):871-90. PubMed ID: 22143405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A two stage conditional power adaptive design adjusting for treatment by covariate interaction.
    Ayanlowo AO; Redden DT
    Contemp Clin Trials; 2008 May; 29(3):428-38. PubMed ID: 18053774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of trial design on the estimation of drug potency and power in clinical trials of haemophilia with inhibitors.
    Larsen MS; Juul RV; Kreilgaard M; Kristensen AT; Simonsson USH
    Eur J Pharm Sci; 2018 Oct; 123():531-538. PubMed ID: 30077714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimality, sample size, and power calculations for the sequential parallel comparison design.
    Ivanova A; Qaqish B; Schoenfeld DA
    Stat Med; 2011 Oct; 30(23):2793-803. PubMed ID: 21805484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flexible two-stage design with sample size reassessment for survival trials.
    Desseaux K; Porcher R
    Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing crossover trial design for rare diseases: limiting ineffective exposure and increasing study power by enabling patient choice to escape early.
    Huang B; Giannini EH; Lovell DJ; Ding L; Liu Y; Hashkes PJ
    Contemp Clin Trials; 2014 Jul; 38(2):204-12. PubMed ID: 24833067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: application to antidepressant trials.
    Boessen R; Knol MJ; Groenwold RH; Grobbee DE; Roes KC
    Clin Trials; 2012 Oct; 9(5):578-87. PubMed ID: 23060319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size re-estimation and other midcourse adjustments with sequential parallel comparison design.
    Silverman RK; Ivanova A
    J Biopharm Stat; 2017; 27(3):416-425. PubMed ID: 28166457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.
    Tamura RN; Huang X
    Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial.
    Xiong C; Yu K; Gao F; Yan Y; Zhang Z
    Clin Trials; 2005; 2(5):387-93. PubMed ID: 16317808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A small n sequential multiple assignment randomized trial design for use in rare disease research.
    Tamura RN; Krischer JP; Pagnoux C; Micheletti R; Grayson PC; Chen YF; Merkel PA
    Contemp Clin Trials; 2016 Jan; 46():48-51. PubMed ID: 26586608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blinded sample size re-estimation in three-arm trials with 'gold standard' design.
    Mütze T; Friede T
    Stat Med; 2017 Oct; 36(23):3636-3653. PubMed ID: 28608469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conditional power calculations for clinical trials with historical controls.
    Korn EL; Freidlin B
    Stat Med; 2006 Sep; 25(17):2922-31. PubMed ID: 16479548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of information and optimal clinical trial design.
    Willan AR; Pinto EM
    Stat Med; 2005 Jun; 24(12):1791-806. PubMed ID: 15806619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.